- Home
- EMD vs CGEM Comparison
EMD vs CGEM Comparison
Compare EMD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | CGEM |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.9M | 671.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EMD | CGEM |
|---|---|---|
| Price | $10.88 | $9.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 248.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $5.68 |
| 52 Week High | $9.55 | $13.33 |
Technical Indicators
Market Signals| Indicator | EMD | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 47.32 |
| Support Level | $10.71 | $9.48 |
| Resistance Level | $10.67 | $13.10 |
| Average True Range (ATR) | 0.12 | 0.95 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 95.45 | 12.71 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.